Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoCellular Therapeutics Ltd (NYSE American:IMUC)

0.334
Delayed Data
As of 3:59pm ET
 -0.001 / -0.30%
Today’s Change
0.25
Today|||52-Week Range
6.32
-83.71%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$5.3M

Company Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.

Contact Information

ImmunoCellular Therapeutics Ltd.
23622 Calabasas Road
Calabasas California 91302
P:(818) 264-2300
Investor Relations:

Employees

Shareholders

Other institutional6.04%
Mutual fund holders0.75%
Individual stakeholders0.06%

Top Executives

Gary S. TitusChairman & Secretary
Anthony J. GringeriPresident, Chief Executive Officer & Director
David E. FractorChief Financial Officer
Steven J. SwansonSenior Vice President-Research